Spots Global Cancer Trial Database for An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
Official Title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)
Study ID: NCT02581631
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).
Detailed Description:
Keywords
Eligibility
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0017, Birmingham, Alabama, United States
University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Local Institution - 0012, Tampa, Florida, United States
Winship Cancer Institute., Atlanta, Georgia, United States
University Of Chicago, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University School Of Medicine, Saint Louis, Missouri, United States
Local Institution - 0003, New York, New York, United States
Local Institution - 0010, New York, New York, United States
University Of Rochester, Rochester, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Providence Portland Medical Center, Portland, Oregon, United States
Bon Secours-St Francis Hosp, Greenville, South Carolina, United States
University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
Local Institution - 0011, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Hopital Saint Louis, Paris, , France
Local Institution - 0020, Pierre Benite Cedex, , France
Local Institution - 0018, Bergamo, , Italy
Local Institution - 0024, Bologna, , Italy
Istituto Clinico Humanitas, Rozzano (milano), , Italy
Local Institution - 0027, Hospitalet de Llobregat - Barcelona, , Spain
Churchill Hospital, Oxford, Oxfordshire, United Kingdom
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
